The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for ProPharma Group Holdings sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Smarter leaders trust GlobalData
ProPharma Group Holdings LLC (ProPharma Group) is a provider of regulatory, clinical and compliance services for the life sciences industry. The company’s services include regulatory sciences, clinical research solutions, research and development technology, quality and compliance, pharmacovigilance and medical information. It has expertise in oncology, cardiovascular, cell and gene therapy, central nervous system (CNS), infectious diseases and vaccines, medical devices and diagnostics, ophthalmology, pediatrics rare and orphan diseases and respiratory therapeutic areas. ProPharma Group operates as a research consulting organization (RCO) that offers solutions like discovery and development, pre-clinical research, clinical development, health authority, post-market monitoring, medical device and diagnostics. It serves pharmaceutical, biotechnology and medical device companies. The company operates across the US, Canada, the UK, India, Australia, Japan, Germany, the Netherlands and Sweden. ProPharma Group is headquartered in Raleigh, North Carolina, the US. Key subsidiaries of ProPharma Group Holdings include Kateric, Clinres farmacija, Treximo, Digital Lab Consulting and Xendo.
The key metrics of ProPharma Group Holdings related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:
As ProPharma Group Holdings is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as ProPharma Group Holdings.
For a detailed understanding of the performance of ProPharma Group Holdings, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.
